# A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

> **NCT05193214** · PHASE2 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Recombinant anti-PD-1 humanized monoclonal antibody injection

## Key facts

- **NCT ID:** NCT05193214
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-25
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05193214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05193214, "A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05193214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*